The stock market may be waking up to the possibility that Pfizer may go bankrupt due to the upcoming covid injection claims.
Many parallels can be drawn between the corporate behaviours of Pfizer and Purdue Pharma, another pharmaceutical concern that dishonestly and aggressively marketed harmful products.
Purdue Pharma went bankrupt due to the greed and depravity of its leaders, as their “legal protections” evaporated. The same may happen to Pfizer.
Old, experienced vaccine companies like GSK refused to participate in “covid vaccines” – and we now see why they made the right choice, writes Igor Chudov.
By Igor Chudov
Take a look at THIS chart: Pfizer’s stock (“PFE”) is valued at 25% less than it was five years ago, despite the billions of dollars it received from the sales of covid vaccines, and the stock market and the pharmaceuticals index having gone up:
At first sight, Pfizer, a worldwide pharmaceutical juggernaut, should not be worth less than before the pandemic. Pfizer’s covid vaccine made it billions and should have added value to the company, even if future sales of covid-specific products cannot be assured. And yet, PFE has inexorably fallen since last November and is worth 25% less than five years ago, defying the general upside tendencies seen for other pharmaceuticals and the stock market.
Since November of 2022, Pfizer has deviated from the trend of the pharmaceuticals index, underperforming by 35%.
This can only be explained by the capital markets seeing something uniquely troublesome for Pfizer. This post will explore what it may be.
I am far from the first person suggesting that Pfizer, which aggressively marketed its covid vaccines and underwrote a worldwide influence operation to mandate its product, may face ruinous liabilities.
Ed Dowd, a former asset manager, was one of the first people to realise that. He explained that legal protection granted to Pfizer by the PREP act will cease to protect it if significant fraud on the part of Pfizer is discovered.